Cardiovascular Screening in Asymptomatic South Asians

Launched by SANDWELL & WEST BIRMINGHAM HOSPITALS NHS TRUST · Jan 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how to better identify and manage cardiovascular disease (CVD) risk in South Asian individuals who do not show any symptoms but may still be at high risk for heart problems. Researchers want to see if using a special heart scan called Computed Tomography Coronary Angiography (CTCA) is more effective than a standard risk assessment tool (the QRISK® 3 score) in finding undetected heart issues in these patients. The goal is to offer better prevention strategies for those who are asymptomatic but have risk factors like high blood pressure, diabetes, or a family history of heart disease.

To participate in this trial, you need to be a South Asian man aged 30 to 60 or a woman aged 50 to 60 who does not have any symptoms of heart disease but has at least one of the listed risk factors. If you join the study, you will be randomly assigned to either the CTCA scan group or the QRISK® 3 score group to help determine the best approach for managing your heart health. It's important to know that this trial is not currently recruiting participants, and there are specific criteria that might exclude some individuals, such as those with a history of heart problems or certain medical conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Asymptomatic South Asian patients of age
• • men≥30 years ≤60 years
• • Women \>50 years ≤60 years
• Plus at least one of the following risk factors:
• • hypertension (HTN)
• • diabetes mellitus (DM)
• • hyperlipidaemia
• • family history of premature coronary artery disease (male \<45 years, female \<55 years)
• • smoking (current or ex-smoker in the last 3 months)
• Exclusion Criteria:
• • Patients meeting any of the following criteria will be excluded
• • Patients unable to give written informed consent
• • History of previous coronary events/CABG/ coronary stenting or CTCA in the last 4 years
• • Patients with pre-existing cardiac symptoms
• • Patients who could or are pregnant
• • Allergy to iodine contrast
• • Active ongoing malignancy and treatment for the same
• • eGFR ≤30ml/min/1.72m2
• • Participation in any other interventional research trial